Kala Pharmaceuticals, Inc. (KALA): Price and Financial Metrics

Kala Pharmaceuticals, Inc. (KALA): $7.20

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

KALA Price/Volume Stats

Current price $7.20 52-week high $19.35
Prev. close $7.20 52-week low $5.10
Day low $7.20 Volume 16,000
Day high $7.30 Avg. volume 27,301
50-day MA $7.45 Dividend yield N/A
200-day MA $9.23 Market Cap 20.28M

KALA Stock Price Chart Interactive Chart >


Kala Pharmaceuticals, Inc. (KALA) Company Bio


Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.


KALA Latest News Stream


Event/Time News Detail
Loading, please wait...

KALA Latest Social Stream


Loading social stream, please wait...

View Full KALA Social Stream

Latest KALA News From Around the Web

Below are the latest news stories about KALA BIO INC that investors may wish to consider to help them evaluate KALA as an investment opportunity.

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ---- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM award, expected to fund operations into 2Q 2025 -- ARLINGTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe

Yahoo | November 13, 2023

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 1,910 shares of its common stock to one new employee. The stock options were granted on September 15, 2023. The grant

Yahoo | September 20, 2023

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded presentation will be made available beginning on Monday, September 11, 2023 at 7:

Yahoo | September 5, 2023

Sidoti Events, LLC’s Virtual August Micro-Cap Conference

Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subject to change.

Yahoo | August 15, 2023

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarded $15 million grant by California Institute for Regenerative Medicine (CIRM) to support ongoing KPI-012 program for the treatment of PCED ---- Rebranded to KALA BIO, Inc. reflecting focus on advancing biologics for the treatment of rare, serious ophthalmic diseases ---- As of June 30, 2023, $59.2 mi

Yahoo | August 4, 2023

Read More 'KALA' Stories Here

KALA Price Returns

1-mo -4.38%
3-mo -8.28%
6-mo -6.25%
1-year -56.70%
3-year -98.07%
5-year -98.11%
YTD 2.86%
2023 -81.65%
2022 -36.94%
2021 -82.15%
2020 83.74%
2019 -24.54%

Continue Researching KALA

Want to see what other sources are saying about Kala Pharmaceuticals Inc's financials and stock price? Try the links below:

Kala Pharmaceuticals Inc (KALA) Stock Price | Nasdaq
Kala Pharmaceuticals Inc (KALA) Stock Quote, History and News - Yahoo Finance
Kala Pharmaceuticals Inc (KALA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!